Abstract: A directional radiation detection system and an omnidirectional radiation detector. The omnidirectional radiation detector detects radiation comprising at least one of: (i) gamma rays; and (ii) neutron particles. A radiation scatter mask (RSM) of the radiation detection system includes a rotating sleeve received over the omnidirectional radiation detector and rotating about a longitudinal axis. The RSM further includes: (i) a fin extending longitudinally from one side of the rotating sleeve; and (ii) a wall extending from the rotating sleeve and spaced apart from the fin having an upper end distally positioned on the rotating sleeve spaced apart or next to from a first lateral side of the fin and a lower end proximally positioned on the rotating sleeve and spaced apart from or next to a second lateral side of the fin.

Abstract: A directional radiation detection system and an omnidirectional radiation detector. The omnidirectional radiation detector detects radiation comprising at least one of: (i) gamma rays; and (ii) neutron particles. A radiation scatter mask (RSM) of the radiation detection system includes a rotating sleeve received over the omnidirectional radiation detector and rotating about a longitudinal axis. The RSM further includes: (i) a fin extending longitudinally from one side of the rotating sleeve; and (ii) a wall extending from the rotating sleeve and spaced apart from the fin having an upper end distally positioned on the rotating sleeve spaced apart or next to from a first lateral side of the fin and a lower end proximally positioned on the rotating sleeve and spaced apart from or next to a second lateral side of the fin.

Abstract: The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I.

Abstract: Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.

Abstract: The present invention relates to novel compounds having a positive allosteric GÀBAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).